TOP HEADLINES

Featured Story

  • Lilly offers behind-the-scenes look at its decade-long tech transfer for TB drugs

    Eli Lilly has published a how-to paper about its ambitious technology transfer program to help China, India, Russia and South Africa produce two drugs to treat multidrug-resistant tuberculosis. The bottom line is that the undertaking was harder than expected, and while it did not fully achieve all of its goals, it was worth doing.

Sanofi will produce generics of 6 drugs in Dubai

Sanofi, which bought controlling interest in Dubai's Globalpharma in June, will kick off production there with generics of 6 of its drugs. Sanofi is now managing the facility.

Novo hiring 90 workers for its new plant in New Hampshire

Novo Nordisk in August bought a plant in New Hampshire that Japan's Olympus Biologics was giving up. Now it is looking for people to help operate it.

Serum Institute of India to invest $160M in new plant

The vaccinemaker Serum Institute of India, which jumped into the biosimilars race in July, is expanding its manufacturing network both in India and the Netherlands. The company says it will invest about $163 million for a new facility in its home country.

More heat applied to Genentech CEO for supply-chain decision on cancer drugs

Genentech CEO Ian Clark is again being publicly chastised for his company's decision to move three of its best-selling cancer drugs to specialty distributors. Groups representing more than 5,000 hospitals say, besides higher costs, the move is as likely to encourage counterfeiting as to deter it.

Hikma gets FDA warning letter for plant in Portugal

Hikma Pharmaceuticals got a closeout notice in March for a warning letter that had been hanging over its West-Ward plant in New Jersey. But at nearly the same time, inspectors were looking over a Hikma facility in Portugal, and the Jordan-based company says the FDA has now issued a warning letter for its sterile injectables plant there.

MORE NEWS

From Our Sister Sites

FiercePharma

Express Scripts--which has made its feelings well known when it comes to the high cost of Gilead's next-gen hepatitis C drugs--says it may quickly change its preferred drug formulary to favor a anticipated challenger from the Illinois company, Reuters reports, provided it's clinically equivalent--and less expensive, of course.

FiercePharma

Impax Laboratories, which has struggled for several years to get its Parkinson's drug Rytary to market, is moving away from early-stage research and has cut its R&D staff by 42 jobs, a 25% reduction to save money.